Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by bringon10baggeron Apr 05, 2020 7:49pm

120 Views

Post# 30881430

RE:Re: Week Six

Yellowknifer.....Thanks for your comments and most importantly thanks for the work you do on the frontline.......Stay Safe! Cheers...........

Yellowknifer69 wrote: Hello and good evening Antibe shareholders!

Greetings from the Covid frontline. Hope you and your family are all keeping well. Yesterday morning we lost a great Registered Nurse from Henry Ford Hospital - just 54 years old, what a shame.

So this is the end of day 9 straight for me with no end in sight. but I thought I would take a minute to catch up on BB comments.

Totally in agreement that Phase 2 was designed to test pain efficacy - nothing more. So not sure why the naysayers want to try and dig deeper into the trial? Nothing there. Phase 3 will expand upon phase 1 and 2 results and need to be a little more rigourous in order to satisfy FDA standards.

Pretty clear, no?

Regardless of the outcome, this company has some innovative therapies going on and given how the markets are suffering I would advise staying long. Incidently, I see that Gilead has posted a fourth Q result of GAAP earning of $6.45 per share. So I guess the market is not killing their cash flow.

Would not be disappointed to see them gobble us up for $2 billion dollars right now, huh,huh, eh?

Okay wishful thinking aside. I am looking forward to seeing Week 6 news release. fingers crossed that ATE proves Montreal Man wrong. Lol!

Lets get it rolling boys!

Stay long and stay Covid free. Incidently, use of face masks and sanitizer are highly advised.
You do not want to get this shyte.

Yellowknifer